Summary The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium
(CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics …

BACKGROUND Historical accounts linking cancer and microbes date as early as four
millennia ago. After establishment of the germ theory of infectious diseases, clinical research …

Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we
analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 …

The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …

Molecular cancer biomarkers are any measurable molecular indicator of risk of cancer,
occurrence of cancer, or patient outcome. They may include germline or somatic genetic …

The discovery of regulated cell death processes has enabled advances in cancer treatment.
In the past decade, ferroptosis, an iron-dependent form of regulated cell death driven by …

Background: Anaplastic thyroid cancer (ATC) is a rare but highly lethal form of thyroid
cancer. Since the guidelines for the management of ATC by the American Thyroid …

Clear cell renal cell carcinomas (ccRCCs) represent∼ 75% of RCC cases and account for
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …

Metastatic disease is responsible for the majority of cancer-related deaths. We report the
longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …